Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLavSyn: FOLFOXIRI + Bevacizumab in mCRC with High LDH and CD138
NCT03117972Phase 2Terminated
- Sponsor
- CHU de Besançon
- Start
- Aug 2017
- Primary completion
- Aug 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan, oxaliplatin, fluorouracil, folinic acid in metastatic colorectal cancer (mCRC), sponsored by CHU de Besançon. Started Aug 2017; status: terminated.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03117972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117972.